New hope for HIV patients with organ transplants: simpler drug combo under study

NCT ID NCT03360682

Completed Disease control Sponsor: Fundacion Clinic per a la Recerca Biomédica Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a combination of HIV drugs (dolutegravir plus two NRTIs) in 19 HIV-positive people who had received a solid organ transplant (heart, liver, or kidney). The goal was to see how the HIV drugs interact with transplant medications and whether the regimen is safe and effective. Participants took the drugs for 48 weeks, and researchers monitored drug levels, viral load, and immune cell counts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dolutegravir, lamivudine, abacavir, tenofovir disoproxil, emtricitabine
What this could lead to: If successful, this could show that a simpler HIV drug regimen is safe and effective for people who have had an organ transplant.
What could go wrong: This is a very small pilot study with only 19 participants, so results may not apply to everyone. Drug interactions with transplant medications could still cause problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION SOLID ORGAN TRANSPLANT

Contacts and locations

Locations

Hospital Clínic de Barcelona

Barcelona, 08036, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.